Moreover, the results of a phase 2 trial showed that early triple antiviral therapy (combined IFN-β1b, lopinavir/ritonavir, and ribavirin) was safe and had a better effect in patients with mild-to-moderate COVID-19 for alleviating symptoms, shortening the time of viral shedding and hospital stay than lopinavir/ritonavir alone (61). Here, IFNA1 is linked to COVID-19.